AliveGen USA
AliveGen is a clinical-stage biopharmaceutical company focused on discovering and developing novel biotherapeutics for high unmet medical needs, including muscle wasting disorders, obesity, cardiometabolic diseases, neuromuscular disorders, chronic kidney disease, nonalcoholic fatty liver disease, fibrotic diseases, osteosarcopenia, blood disorders, and cancer. Founded in 2014 and located in Thousand Oaks, California, the company aims to improve patient care and quality of life through innovative and safe therapies, utilizing cutting-edge biotechnology.
Industries
Nr. of Employees
small (1-50)
AliveGen USA
Thousand Oaks, California, United States, North America
Products
ALG-801
Clinical-stage therapeutic candidate; completed Phase 1a and Phase 1b multiple-ascending dose clinical trials.
ALG-802
Therapeutic candidate in preclinical development with ongoing CMC activities.
Multiple novel candidates (preclinical)
Several additional discovery-stage biotherapeutic candidates in preclinical development.
ALG-801
Clinical-stage therapeutic candidate; completed Phase 1a and Phase 1b multiple-ascending dose clinical trials.
ALG-802
Therapeutic candidate in preclinical development with ongoing CMC activities.
Multiple novel candidates (preclinical)
Several additional discovery-stage biotherapeutic candidates in preclinical development.
Expertise Areas
- Clinical trial management
- Clinical operations and global site networks
- Biologics and protein therapeutic development
- CMC and manufacturing process development
Key Technologies
- Protein engineering
- Biologics manufacturing and purification
- CMC (chemistry, manufacturing and controls)
- Preclinical models and lead optimization